Open AccessInfant Growth Outcomes After Maternal Tenofovir Disoproxil Fumarate Use During Pregnancy
Author(s) -
Carla E. Ransom,
Yanling Huo,
Kunjal Patel,
Gwendolyn B. Scott,
Heather Watts,
Paige L. Williams,
George K. Siberry,
Elizabeth Livingston
Publication year - 2013
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e3182a7adb2
Subject(s) - medicine , pregnancy , birth weight , underweight , low birth weight , gestational age , obstetrics , confidence interval , odds ratio , in utero , population , regimen , gestation , pediatrics , fetus , body mass index , biology , overweight , genetics , environmental health
To determine whether maternal use of tenofovir disoproxil fumarate for treatment of HIV in pregnancy predicts fetal and infant growth.